Jade reports interim Phase I results of JADE101 for IgAN
Key findings show mean IgA reductions of around 70% from baseline, sustained at 12 weeks at the 700mg dose.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance